Table 1 Inputs for deterministic sensitivity analysis
Parameter | Mean (range) |
|---|---|
Discount rate—costs, % | 3 (0–6) |
Discount rate—outcomes, % | 3 (0–6) |
Average body weight, kg | 71.4 (57.1–85.7) |
Cost—PF state, $US | 65.67 (52.53–78.80) |
Cost—PD state, $US | 91.61 (73.29–109.93) |
Terminal cost, $US | 10,713.01 (8570.41–12,855.61) |
Administration cost, $US | |
Nivolumab | 139.61 (111.69–167.53) |
Everolimus | Not applicablea |
Monitoring cost, $US | |
Nivolumab | 79.67 (63.74–95.60) |
Everolimus | 79.67 (63.74–95.60) |
Utility weight, PF, response | |
Nivolumab | 0.895 (0.889–0.901) |
Everolimus | 0.895 (0.889–0.901) |
Utility weight, PF, no response | |
Nivolumab | 0.846 (0.840–0.852) |
Everolimus | 0.846 (0.840–0.852) |
Utility weight, PD | |
Nivolumab | 0.817 (0.811–0.823) |
Everolimus | 0.817 (0.811–0.823) |